Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Benzinga Insights

What the Options Market Tells Us About Novo Nordisk

Financial giants have made a conspicuous bearish move on Novo Nordisk. Our analysis of options history for Novo Nordisk (NYSE:NVO) revealed 14 unusual trades.

Delving into the details, we found 35% of traders were bullish, while 50% showed bearish tendencies. Out of all the trades we spotted, 5 were puts, with a value of $210,005, and 9 were calls, valued at $379,290.

Predicted Price Range

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $105.0 to $111.0 for Novo Nordisk over the last 3 months.

Insights into Volume & Open Interest

Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Novo Nordisk's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Novo Nordisk's significant trades, within a strike price range of $105.0 to $111.0, over the past month.

Novo Nordisk 30-Day Option Volume & Interest Snapshot

Largest Options Trades Observed:

Symbol PUT/CALL Trade Type Sentiment Exp. Date Ask Bid Price Strike Price Total Trade Price Open Interest Volume
NVO CALL SWEEP NEUTRAL 12/13/24 $5.6 $5.05 $5.29 $105.00 $159.0K 171 300
NVO PUT TRADE NEUTRAL 12/20/24 $8.35 $8.0 $8.2 $110.00 $42.6K 7.0K 273
NVO PUT TRADE BULLISH 12/20/24 $8.2 $8.1 $8.1 $110.00 $42.1K 7.0K 116
NVO PUT TRADE BULLISH 12/20/24 $8.2 $8.1 $8.1 $110.00 $42.1K 7.0K 64
NVO PUT TRADE BULLISH 12/20/24 $7.7 $7.5 $7.5 $109.00 $42.0K 351 56

About Novo Nordisk

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Where Is Novo Nordisk Standing Right Now?

  • Trading volume stands at 358,592, with NVO's price down by -0.65%, positioned at $105.44.
  • RSI indicators show the stock to be is currently neutral between overbought and oversold.
  • Earnings announcement expected in 61 days.

Expert Opinions on Novo Nordisk

1 market experts have recently issued ratings for this stock, with a consensus target price of $160.0.

Unusual Options Activity Detected: Smart Money on the Move

Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. Click here for access. * An analyst from Cantor Fitzgerald downgraded its action to Overweight with a price target of $160.

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.

If you want to stay updated on the latest options trades for Novo Nordisk, Benzinga Pro gives you real-time options trades alerts.

Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.